Cytomegalovirus Disease After Liver Transplant—A Description of a Treatment-Resistant Case: A Case Report and Literature Review

Czarnecka, Paulina; Czarnecka, Kinga; Tronina, Olga; Durlik, Magdalena

doi:10.1016/j.transproceed.2018.05.014

Cited by 6 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both artesunate, an antimalarial drug, and leflunomide, an immunosuppressant, demonstrate in vitro activity against CMV (228)(229)(230). Leflunomide has been used for resistant CMV in case series and case reports, but definitive evidence of a clinical benefit is lacking (231)(232)(233)(234)(235)(236). Leflunomide is limited by hepatoxicity and marrow suppression (237,238).…”

Section: Newer Drugs and Approaches For Resistant/refractory CMV Novel Agentsmentioning

confidence: 99%

Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation

2020

View full text Add to dashboard Cite

SUMMARY Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.

show abstract

Section: Newer Drugs and Approaches For Resistant/refractory CMV Novel Agentsmentioning

confidence: 99%

Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation

2020

View full text Add to dashboard Cite

show abstract

“…The incidence of CMV resistance in liver transplant patients is not well defined, however it is believed that in solid organ transplants in general it is around 7% in high risk patients[ 68 , 69 ]. When ganciclovir and valganciclovir are shown to be ineffective due to resistance, patients should be treated with combination therapy, foscarnet and cidofovir or experimental treatments[ 70 ].…”

Section: Therapymentioning

confidence: 99%